SEATTLE, Wash., and REDWOOD CITY, Calif., January 25, 2006—Rosetta Biosoftware and Ingenuity Systems today announced a collaboration to establish interoperability between the Rosetta Resolver® system and the IPA system. Researchers will be able to easily exchange data between the two systems to leverage both systems’ ability to analyze gene expression data and perform advanced pathway analysis.
“The Rosetta Resolver system is a comprehensive informatics solution for analyzing large amounts of data in preclinical and clinical studies or for research diagnostic purposes,” said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. “We are pleased to provide seamless integration between Ingenuity’s pathway analysis tools and the Rosetta Resolver system to our mutual customers, allowing them to uncover mechanisms of action, predict potential toxicities, and give biological meaning to their gene expression data.”
“Connecting the Ingenuity Pathway Analysis solution with the Resolver system will increase the capabilities for our joint customers to derive increased understanding and insights from gene expression data,” said Tuan Nguyen, VP, Partner and Professional Services of Ingenuity Systems.“ This collaboration represents an important step in our strategy to seamlessly integrate IPA into the natural workflow of our customers.”
The Rosetta Resolver system is developed and supported by Rosetta Biosoftware and is distributed exclusively by Agilent Technologies.
About Ingenuity Systems
Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotechnology companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan. For more information, visit www.ingenuity.com
About the Rosetta Resolver System
The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats, including Agilent DNA microarrays, and applies Rosetta Biosoftware’s proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results.
Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Aventis Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline and Merck & Co., Inc., as well as premier academic institutions such as the Harvard University Center for Genomics Research. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com.
About Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its enterprise software solutions, including the Rosetta Resolver and Rosetta Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE: MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics’ technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics’ technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.
Rosetta Resolver and Rosetta Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.